Preventing joint damage in early psoriatic arthritis
Treatments studied
Part of Bones, joints & muscles, Skin clinical trials.
This trial tests if a treatment can prevent joint damage in people recently diagnosed with psoriatic arthritis. It compares a standard medication (methotrexate) with or without a newer biologic drug (adalimumab) to see which is better at stopping the disease from causing lasting harm.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have had psoriatic arthritis symptoms for 2 years or less
- You have joint pain and swelling (at least one tender and one swollen joint) even after trying anti-inflammatory drugs for 4 weeks
- You have at least one risk factor for worse disease, like many affected joints, signs of joint damage on scans, high inflammation in blood tests, dactylitis (whole finger or toe swelling), nail changes, or difficulty with daily tasks
- You do not have severe deformities in your hand joints
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, LPX-TI641, to see if it is safe and how it works in the body for people with rheumatoid arthritis or psoriatic arthritis. It may be an option if you have active joint swelling and pain despite standard treatments.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study tests a methotrexate injection (given under the skin) for people with moderate to severe rheumatoid arthritis who haven't taken methotrexate before. Researchers want to see how the medicine builds up in your body and if it helps control your symptoms.
This trial tests whether increasing your methotrexate dose or switching from pills to injections can better control active rheumatoid arthritis. It's for people already taking a stable, moderate dose of methotrexate but still having joint swelling and symptoms.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
This trial compares two medicine options (azathioprine vs methotrexate) when added to adalimumab to treat active Crohn’s disease. It may help determine which add-on works better for people whose Crohn’s is still active despite standard treatments or who can’t take them.
Hear when a new Psoriatic Arthritis (PsA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.